Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.

被引：16

作者：

Kalinsky, Kevin ^{[1
]}

Bianchini, Giampaolo ^{[2
]}

Hamilton, Erika P. ^{[3
]}

Graff, Stephanie L. ^{[4
]}

Park, Kyong Hwa ^{[5
]}

Jeselsohn, Rinath ^{[6
]}

Demirci, Umut ^{[7
]}

Martin, Miguel ^{[8
,9
]}

Layman, Rachel M. ^{[10
]}

Hurvitz, Sara A. ^{[11
,12
]}

Sammons, Sarah L. ^{[6
]}

Kaufman, Peter A. ^{[13
]}

Munoz, Montserrat ^{[9
,14
]}

Tseng, Ling-Ming ^{[15
]}

Knoderer, Holly ^{[16
]}

Nguyen, Bastien ^{[16
]}

Zhou, Yanhong ^{[16
]}

Ravenberg, Elizabeth ^{[16
]}

Litchfield, Lacey M. ^{[16
]}

Wander, Seth Andrew ^{[17
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[2] IRCCS Osped San Raffaele, Milan, Italy

[3] Sarah Cannon Res Inst, Nashville, TN USA

[4] Brown Univ, Lifespan Canc Inst, Legorreta Canc Ctr, Providence, RI USA

[5] Korea Univ, Anam Hosp, Dept Internal Med, Div Med Oncol,Coll Med, Seoul, South Korea

[6] Dana Farber Canc Inst, Boston, MA USA

[7] Uskudar Univ, Fac Med, Mem Ankara Hosp, Med Oncol, Ankara, Turkiye

[8] Inst Invest Sanitaria Gregorio Maranon, Madrid, Spain

[9] GEICAM Spanish Breast Canc Grp, Madrid, Spain

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[11] Univ Washington, Sch Med, Seattle, WA USA

[12] Fred Hutchinson Canc Ctr, Seattle, WA USA

[13] Univ Vermont, Canc Ctr, Burlington, VT 05405 USA

[14] Hosp Clin Barcelona, Barcelona, Spain

[15] Taipei Vet Gen Hosp, Taipei, Taiwan

[16] Eli Lilly & Co, Indianapolis, IN USA

[17] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.17_suppl.LBA1001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：LBA1001 / LBA1001

页数：1

共 50 条

[1] Abemaciclib plus fulvestrant for HR+, HER2-advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial
Bianchini, G.
Jimenez, M. Martin
Graff, S.
Jeselsohn, R.
Wander, S.
Layman, R.
Hurvitz, S. A.
Hamilton, E. P.
Sammons, S.
Kaufman, P.
Knoderer, H.
Nguyen, B.
Zhou, Y.
Ravenberg, E.
Litchfield, L.
Kalinsky, K.
ANNALS OF ONCOLOGY, 2024, 35 : S362 - S363
[2] postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy
Kalinsky, Kevin
Layman, Rachel M.
Kaufman, Peter A.
Graff, Stephanie L.
Bianchini, Giampaolo
Martin, Miguel
Zhou, Yanhong
Knoderer, Holly
Litchfield, Lacey
Andrew Wander, Seth
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Kalinsky, Kevin
Bianchini, Giampaolo
Hamilton, Erika
Graff, Stephanie L.
Park, Kyong Hwa
Jeselsohn, Rinath
Demirci, Umut
Martin, Miguel
Layman, Rachel M.
Hurvitz, Sara A.
Sammons, Sarah
Kaufman, Peter A.
Munoz, Montserrat
Lai, Jiun-, I
Knoderer, Holly
Sandoval, Cynthia
Chawla, Aarti R.
Nguyen, Bastien
Zhou, Yanhong
Ravenberg, Elizabeth
Litchfield, Lacey M.
Smyth, Lillian
Wander, Seth A.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (09)
[4] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
Corona, Silvia Paola
Generali, Daniele
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
[5] MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2-advanced breast cancer
Sledge, G. W.
Toi, M.
Neven, P.
Sohn, J.
Inoue, K.
Pivot, X.
Burdaeva, O.
Okera, M.
Masuda, N.
Kaufman, P. A.
Koh, H.
Grischke, E-M.
Conte, P. F.
Lu, Y.
Barriga, S.
Hurt, K.
Frenzel, M.
Johnston, S. R. D.
Llombart-Cussac, A.
ANNALS OF ONCOLOGY, 2019, 30 : 856 - 856
[6] Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer that had exhibited primary or secondary resistance to prior endocrine therapy
Foster, C.
Pivot, X.
Llombart-Cussac, A.
Neven, P.
Lin, Y.
Kaufman, P. A.
Sledge, Jr G. W.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 289 - 290
[7] Monarch 2: Interim Overall Survival of Abemaciclib Plus Fulvestrant in Patients with HR+, HER2-Advanced Breast Cancer
Grischke, Eva Maria
Sledge, George W.
Toi, Masakazu
Neven, Patrick
Sohn, Joo Hyuk
Inoue, Kenichi
Pivot, Xavier
Burdaeva, Olga
Masuda, Norikazu
Kaufman, Peter
Koh, Han
Conte, Pierfranco
Barriga, Susana
Hurt, Karla
Frenzel, Martin
Johnston, Stephen
Llombart-Cussac, Antonio
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 15 - 15
[8] Abemaciclib plus fulvestrant in participants with HR+/HER2-advanced breast cancer: A pooled analysis of the endocrine therapy naive (EN) participants in MONARCH 2
Luis-Gonzalez Trujillo, J.
Escobar Gomez, M.
Sohn, J. H.
Im, Y-H.
Wang, H-C.
Cussac, A. Llombart
Zhang, W.
Haddad, N.
Wasserstrom, H.
van Hal, G.
Sledge, G. W., Jr.
ANNALS OF ONCOLOGY, 2021, 32 : S464 - S465
[9] MONARCHplus: A phase III trial of abemaciclib plus nonsteroidal aromatase inhibitor (NSAI) or fulvestrant (F) for women with HR+/HER2-advanced breast cancer (ABC)
Jiang, Z.
Hu, X.
Zhang, Q.
Sun, T.
Yin, Y.
Li, H.
Costa, R.
Yan, M.
Oppermann, C.
Tong, Z.
Liu, Y.
Zhang, Y.
Cheng, Y.
Ouyang, Q.
Chen, X.
Liao, N.
Wu, X.
Wang, X.
Han, R.
Lu, Y.
ANNALS OF ONCOLOGY, 2019, 30 : 863 - 863
[10] A Phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/HER2-advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1)
Hurvitz, Sara A.
Andre, Fabrice
Cristofanilli, Massimo
Curigliano, Giuseppe
Giordano, Antonio
Han, Hyo S.
Martin, Miguel
Pistilli, Barbara
Rugo, Hope S.
Wesolowski, Robert
Suzuki, Samuel
Mutka, Sarah C.
Gorbatchevsky, Igor
Loibl, Sibylle
CANCER RESEARCH, 2023, 83 (08)

← 1 2 3 4 5 →